Mouse TACI/TNFRSF13B Antibody, R&D Systems™

TACI/TNFRSF13B/CVID

Polyclonal

Unconjugated

Q9ET35

TNFRSF13B

Mouse myeloma cell line NS0-derived recombinant mouse TACI/TNFRSF13B Phe5-Thr129 Accession # Q9ET35

100 μg

Primary

Detects mouse TACI/TNFRSF13B in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human TACI is observed and less than 1% cross-reactivity with recombinant mouse BCMA/TNFRSF17 is observed.

Mouse

IgG

Western Blot, Flow Cytometry, Blockade of Receptor-ligand Interaction, CyTOF

LYOPH

Western Blot 0.1 ug/mL, Flow Cytometry 2.5 ug/10^6 cells, Blockade of Receptor-ligand Interaction, CyTOF-ready

CD267, CD267 antigen, CVID, CVID2, FLJ39942, MGC133214, TACIMGC39952, TNFRSF13B, TNFRSF14B, Transmembrane activator and CAML interactor, tumor necrosis factor receptor 13B, tumor necrosis factor receptor superfamily member 13B, tumor necrosis factor receptor superfamily, member 13B

Goat

Affinity Purified

RUO

23495

Reconstitute at 0.2 mg/mL in sterile PBS.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.